Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00568126 · ClinicalTrials.gov registry record · Phase 3
Study of Maca Root for the Treatment of Antidepressant-Induced Sexual Dysfunction in Females
A Phase 3 study of Antidepressant Induced Sexual Dysfunction, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT00568126: Completed Phase 3 study of Antidepressant Induced Sexual Dysfunction, sponsored by Massachusetts General Hospital.
NCT00568126 is a Phase 3 study of Antidepressant Induced Sexual Dysfunction that has completed, run by Massachusetts General Hospital. The registered enrollment target is 45 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00568126, a Phase 3 study of Antidepressant Induced Sexual Dysfunction, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out whether Maca Root is effective for treating sexual dysfunction in females that is caused by antidepressant drugs. An additional aim of the study is to document the safety and tolerability of maca root, as well as any potential side effects that it causes.
Primary Outcome
Arizona Sexual Experience Scale (ASEX) consists of five items rating sexual drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm.The range of total score is 5-30 with the higher scores indicating greater sexual dysfunction. A total final score of 10 or less is considered to indicate remission of sexual dysfunction.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Maca Root
Study Locations (1)
Massachusetts
- Depression Clinical and Research Program, Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2007-12-27 |
| Est. Completion | 2010-10-05 |
| Phase | Phase 3 |
What the finished NCT00568126 record still lists
NCT00568126 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Antidepressant Induced Sexual Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00568126 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00568126 about?
NCT00568126 is a clinical study titled "Study of Maca Root for the Treatment of Antidepressant-Induced Sexual Dysfunction in Females". The purpose of this study is to find out whether Maca Root is effective for treating sexual dysfunction in females that is caused by antidepressant drugs. An additional aim of the study is to document the safety and tolerability of maca root, as well as any potential side effects that it causes.
What is the current status of trial NCT00568126?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 45 participants. The study started on 2007-12-27. Estimated completion is 2010-10-05.
What conditions does trial NCT00568126 study?
This clinical trial studies the following conditions: Antidepressant Induced Sexual Dysfunction.
What interventions are being tested in trial NCT00568126?
The interventions under investigation include: Placebo (DRUG), Maca Root (DRUG).
Who is sponsoring clinical trial NCT00568126?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00568126 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00568126's enrollment target sits among peer trials
45 1870th of 2000 higher than 127 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI